Clinical Trial Update: Study to Assess Hemodynamic Effects, Safety and Tolerability of Chimeric Natriuretic Peptide (CD-NP) in Patients With Stabilized Acute Heart Failure (AHF) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the hemodynamic effects, safety, and tolerability of CD-NP in patients with stabilized acute heart failure has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Decompensated Heart Failure

Drugs mentioned

• CD-NP (CD-NP)

Snippet

Sponsor: Nile Therapeutics | Conditions: Acute Decompensated Heart Failure | Phase 2 | Status: COMPLETED